+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 269 Pages
  • September 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5670554
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Drugs In Development, 2022, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Migraine - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 11, 18, 11, 2, 32, 6 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Migraine - Overview
  • Migraine - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Migraine - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Migraine - Companies Involved in Therapeutics Development
  • Migraine - Drug Profiles
  • Migraine - Dormant Projects
  • Migraine - Discontinued Products
  • Migraine - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Migraine, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Migraine - Dormant Projects, 2022
  • Migraine - Discontinued Products, 2022
List of Figures
  • Number of Products under Development for Migraine, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4P Therapeutics LLC
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Achelios Therapeutics Inc
  • Acherx LLC
  • AEON Biopharma Inc
  • AgoneX Biopharmaceuticals Inc
  • Allodynic Therapeutics LLC
  • Amgen Inc
  • Amneal Pharmaceuticals Inc
  • AOBiome LLC
  • Arovella Therapeutics Ltd
  • Asarina Pharma AB
  • AstraZeneca Plc
  • Astrocyte Pharmaceuticals Inc
  • Avanir Pharmaceuticals Inc
  • Axsome Therapeutics Inc
  • Benuvia Therapeutics Inc
  • Better Life Pharmaceuticals Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Cerecin Pte Ltd
  • Ceruvia Lifesciences LLC
  • Charleston Laboratories Inc
  • Citragen Pharmaceuticals Inc
  • Corium Inc
  • Crossject SA
  • Crystec Ltd
  • Curatis AG
  • DelNova Inc
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Co
  • Epalex Corp
  • Exxel Pharma Inc
  • Gubra ApS
  • H. Lundbeck AS
  • HEC Pharma Co Ltd
  • IACTA Pharmaceuticals Inc
  • InStar Technologies AS
  • IntelGenx Corp
  • Invisio Ltd
  • Ionis Pharmaceuticals Inc
  • Kallyope Inc
  • Kissei Pharmaceutical Co Ltd
  • Klaria Pharma Holding AB
  • Lateral Pharma Pty Ltd
  • MannKind Corp
  • Merck & Co Inc
  • Microgen
  • Mydecine Innovations Group Inc
  • NAL Pharmaceuticals Ltd
  • NeurAxon Pharma Inc
  • NutriBand Inc
  • OWP Pharmaceuticals Inc
  • Panaxia Pharmaceutical Industries Ltd
  • PassPort Technologies Inc (USA)
  • Pharmnovo AB
  • Pherin Pharmaceuticals Inc
  • Pulmatrix Inc
  • Qingdao Chia Tai Haier Pharmaceutical Co Ltd
  • RAFT Pharmaceuticals
  • Revance Therapeutics Inc
  • Saniona AB
  • Satsuma Pharmaceuticals Inc
  • Seurat Therapeutics Inc
  • Shandong Boan Biotechnology Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Sorrento Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • Tremeau Pharmaceuticals Inc
  • Trevena Inc
  • Trigemina Inc
  • TrioxBio Inc
  • Vaxxinity Inc
  • Xoc Pharmaceuticals Inc
  • Zosano Pharma Corp